Diffuse (anergic) cutaneous leishmaniasis responding to amphotericin B.

Area of Science:

• Infectious Diseases
• Parasitology
• Dermatology
• Immunology

Background:

• American cutaneous leishmaniasis is an endemic zoonotic disease in the New World.
• Diffuse cutaneous leishmaniasis (DCL) is a rare, severe manifestation characterized by antigen-specific immunodeficiency.
• DCL presents with widespread, non-ulcerated nodules and plaques, clinically resembling lepromatous leprosy.

Observation:

• Patients with advanced DCL often experience relapses despite aggressive chemotherapy.
• Previous therapeutic strategies for DCL have yielded limited and inconsistent results.
• A severe, exceptional case of DCL was observed.

Findings:

• The severe DCL case reported demonstrated complete resolution following treatment with amphotericin B.
• Amphotericin B, previously considered only mildly effective for DCL, proved successful in this exceptional case.
• This case highlights the potential efficacy of amphotericin B in managing severe DCL.

Implications:

• The findings suggest amphotericin B may be a viable therapeutic option for severe or refractory DCL.
• Further investigation into the role of amphotericin B in DCL treatment is warranted.
• This case contributes valuable information to the therapeutic approach for American cutaneous leishmaniasis.